Meganest

Articaine hydrochloride, the active ingredient in Meganet, is a local anesthetic (amide) presented as a solution for injection for infiltration and perineural use. It provides local anesthesia for dental procedures and minor surgical interventions in adult patients.

GNH USA supplies Meganet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meganet is a local anesthetic used to achieve reversible loss of sensation in tissues supplied by peripheral nerves.

- Dental procedures: provides pain‑free treatment during fillings, extractions and periodontal therapy. - Minor surgical procedures: enables comfortable performance of skin biopsies, suturing and minor excisions. - Oral surgery: facilitates anesthesia for procedures such as tooth extractions and implant placement.

Adverse reactions may occur following administration of Meganet.

Common Side Effects: - Transient numbness at the injection site - Mild swelling or bruising - Headache - Dizziness - Metallic taste - Temporary blurred vision

Serious or Rare Side Effects: - Allergic reaction (rash, itching, anaphylaxis) - Severe hypotension or cardiovascular collapse - Cardiac arrhythmia - Methemoglobinemia - Prolonged or deep tissue anesthesia - Seizures

Meganet should be used with careful assessment of patient history and clinical conditions. - Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular caution: avoid in patients with uncontrolled hypertension, arrhythmias, or severe cardiac disease. - Epinephrine contraindications: avoid in patients with hyperthyroidism, pheochromocytoma, or on non‑selective beta‑blockers. - Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited. - Dosage control: adhere strictly to prescriber‑determined volume and concentration. - Store at below 25°C: keep in the original container, protect from light and moisture.

Meganet may interact with other medications that affect cardiovascular function or catecholamine metabolism.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may potentiate epinephrine‑induced hypertension. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis with epinephrine. - Tricyclic antidepressants: can enhance vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative toxicity risk. - Antihypertensive agents: may blunt epinephrine’s vasoconstrictive action. - Clonidine or other central α2‑agonists: monitor blood pressure changes.